Showing 541 - 560 results of 43,621 for search '(( 50 ((teer decrease) OR (mean decrease)) ) OR ( 5 ((we decrease) OR (nn decrease)) ))', query time: 0.75s Refine Results
  1. 541
  2. 542

    Image 2_Probiotic Limosilactobacillus reuteri KUB-AC5 decreases urothelial cell invasion and enhances macrophage killing of uropathogenic Escherichia coli in vitro study.tiff by Arishabhas Tantibhadrasapa (13929639)

    Published 2024
    “…However, the antibacterial and immune modulatory effects of AC5 on UPEC have never been explored.</p>Methods<p>Here, we investigated both the direct and indirect effects of AC5 against UPEC isolates (UTI89, CFT073, and clinical MDR UPEC AT31) in vitro. …”
  3. 543

    Table 1_Probiotic Limosilactobacillus reuteri KUB-AC5 decreases urothelial cell invasion and enhances macrophage killing of uropathogenic Escherichia coli in vitro study.xlsx by Arishabhas Tantibhadrasapa (13929639)

    Published 2024
    “…However, the antibacterial and immune modulatory effects of AC5 on UPEC have never been explored.</p>Methods<p>Here, we investigated both the direct and indirect effects of AC5 against UPEC isolates (UTI89, CFT073, and clinical MDR UPEC AT31) in vitro. …”
  4. 544

    Image 1_Probiotic Limosilactobacillus reuteri KUB-AC5 decreases urothelial cell invasion and enhances macrophage killing of uropathogenic Escherichia coli in vitro study.tiff by Arishabhas Tantibhadrasapa (13929639)

    Published 2024
    “…However, the antibacterial and immune modulatory effects of AC5 on UPEC have never been explored.</p>Methods<p>Here, we investigated both the direct and indirect effects of AC5 against UPEC isolates (UTI89, CFT073, and clinical MDR UPEC AT31) in vitro. …”
  5. 545
  6. 546
  7. 547
  8. 548
  9. 549
  10. 550
  11. 551
  12. 552
  13. 553
  14. 554
  15. 555
  16. 556
  17. 557
  18. 558
  19. 559
  20. 560